A study found that adults over 55 taking Zepbound (a weight-loss drug) had lower healthcare costs and fewer hospital visits. The finding supports a program that helps older people on Medicare afford the drug.

• •Study found adults over 55 on Zepbound had lower healthcare costs and fewer hospital visits
• •Findings relate to a program helping older Medicare patients afford Zepbound
• •Source: Eli Lilly press release on real-world study data

Eli Lilly launched a Medicare program on July 1 that helps seniors with Medicare Part D insurance get its weight-loss drugs Foundayo (a daily pill) and Zepbound (an injectable). The new pathway makes these medicines more affordable for older patients.

• •Eli Lilly launched a Medicare Part D program on July 1 for Foundayo and Zepbound
• •Foundayo (orforglipron) is a daily pill; Zepbound (tirzepatide) is an injectable
• •Program targets weight management access for Medicare Part D patients

Eli Lilly and basketball star Shaquille O'Neal launched a marketing campaign called Watch This to talk about obstructive sleep apnea (a breathing problem during sleep). Zepbound (tirzepatide) is now approved as the first drug for this condition in adults who also have obesity.

• •Eli Lilly launched a marketing campaign called 'Watch This' featuring Shaquille O'Neal
• •Zepbound (tirzepatide) is approved as the first drug for obstructive sleep apnea in adults with obesity
• •O'Neal said he had lived with obstructive sleep apnea for years before learning it was treatable

Eli Lilly said CVS Caremark will start covering its weight-loss drugs Foundayo and Zepbound for millions of Americans starting in June and October. Eligible patients may pay only $25 per month for their medicine.

• •CVS Caremark will cover Foundayo and Zepbound starting in June and October
• •Eligible patients may pay $25 per month for their medicine

A scientist in Saskatchewan is celebrating major weight loss after using generic semaglutide (the active ingredient in Ozempic). The generic version is becoming available in the Canadian province.

• •Generic semaglutide is becoming available in Saskatchewan, Canada
• •A scientist in Saskatchewan reported major weight loss using generic semaglutide

• •Amazon Pharmacy is offering access to Ozempic pills (oral semaglutide / Rybelsus)
• •Story frames this as a test of Novo Nordisk's pricing power

Novo Nordisk's pill versions of semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) are now available on Amazon with same-day delivery. This expands how patients can buy these drugs, moving beyond traditional pharmacies.

• •Novo's oral Ozempic and Wegovy pills are now on Amazon
• •Amazon offers same-day delivery for the pills
• •Move expands access beyond traditional pharmacies

• •Article covers a new Medicare option for weight-loss drugs aimed at older Americans

• •Russia is seeing a sales boom in obesity drugs

• •Novo Nordisk raised its 2026 outlook
• •Adjusted growth view is more complicated than headline

Amazon Pharmacy started offering same-day delivery for Rybelsus, the pill form of semaglutide (Ozempic). This makes the weight-loss drug faster to get for people who use Amazon's pharmacy service.

• •Amazon Pharmacy now offers same-day delivery for Rybelsus
• •Rybelsus is the pill form of semaglutide (Ozempic)

Amazon Pharmacy now delivers semaglutide (Ozempic) pills and lets customers pick them up at offices. This makes the weight-loss drug easier to get through a major online retailer.

• •Amazon Pharmacy now delivers semaglutide (Ozempic) pills
• •Customers can also pick up the drug at Amazon offices

Canada has approved generic versions of semaglutide (the drug in Ozempic). This could change how Canadian health plans cover the weight-loss drug, potentially shifting costs and access.

• •Canada approved generic versions of semaglutide, the drug in Ozempic
• •Canadian benefit plans may change how they cover the weight-loss drug

Novo Nordisk reported a 40% jump in semaglutide sales in India. The growth shows strong demand for the weight-loss drug in a major emerging market.

• •Novo Nordisk reported a 40% jump in semaglutide sales in India
• •Growth signals strong demand in a major emerging market

Eli Lilly's Foundayo (tirzepatide pill) hit 7,335 prescriptions in its fourth week on the market. The new drug is selling slower than Novo Nordisk's Wegovy, a competing weight-loss injection.

• •Foundayo hit 7,335 prescriptions in its fourth week on the market
• •Foundayo is Lilly's tirzepatide pill
• •Foundayo is selling slower than Novo's Wegovy injection

Eli Lilly's obesity pill reached 7,000 prescriptions in its fourth week on the market. The number suggests a slow start compared to competing weight-loss drugs.

• •Lilly's obesity pill hit 7,000 prescriptions in its fourth week on the market
• •Uptake looks slow versus other weight-loss drugs

Novo Nordisk saw a big jump in Ozempic sales in India. The company is selling more of its semaglutide weight-loss drug in that market.

• •Novo Nordisk reported a surge in Ozempic sales in India
• •Growth is tied to its semaglutide franchise in the Indian market

A generic version of semaglutide (Ozempic) could help employers save money on drug costs, but how much depends on how their health plans are set up. Experts say the actual savings won't be automatic and will vary by company.

• •Generic semaglutide could lower employer drug costs in Canada
• •Savings will depend on how each health plan is set up
• •Experts say cost cuts won't be automatic across employers

Novo Nordisk's sales in India jumped 40% in April, even though generic versions of GLP-1 drugs (weight-loss and diabetes medicines) are now competing in the market. The growth shows strong demand for weight-loss drugs in India despite cheaper alternatives becoming available.

• •Novo Nordisk India sales rose 40% in April
• •Growth came despite new generic GLP-1 competition

Torrent Pharmaceuticals sold 2 million dollars worth of generic semaglutide in India, becoming an early leader in the market for the copied version of the weight-loss drug. The company is one of the first to offer an affordable version of semaglutide in India.

• •Torrent Pharma sold $2 million of generic semaglutide in India
• •Torrent is one of the first to offer a low-cost copy in India

• •Novo Nordisk India sales rose 40%
• •Generic competition is building in the India market

Eli Lilly's new obesity drug retatrutide is so effective that people are already making illegal copies of it. The drug hasn't even been fully approved yet, but compounding pharmacies are producing their own versions.

• •Lilly's obesity drug retatrutide is being copied before full approval
• •Compounding pharmacies are making their own versions of the drug

• •Wegovy posted major sales in the period covered
• •Profits hit new highs alongside the sales gains

Novo Nordisk cut prices on Wegovy and Ozempic in India and saw sales jump 40% in April. The price cuts made the weight-loss and diabetes drugs more affordable in that market.

• •Novo Nordisk India sales rose 40% in April
• •Growth followed price cuts on Wegovy and Ozempic
• •Price cuts applied in the India market

India's market for GLP-1 drugs (weight-loss and diabetes medicines) grew tenfold as generic copies of semaglutide became available. The cheaper generics expanded the number of people who could afford these drugs.

• •India's GLP-1 drug market grew 10 times after semaglutide generics launched
• •Generic semaglutide copies are now available in India
• •Lower prices expanded patient access to weight-loss and diabetes drugs

Novo Nordisk's CEO says the pill form of Wegovy (semaglutide) is selling faster than ever in the United States. The company sees strong demand for the oral version of its weight-loss drug.

• •Novo's CEO called the US launch of oral Wegovy a record-breaking start
• •Oral Wegovy uses semaglutide, the same drug as the Wegovy shot
• •Novo reports strong early US demand for the pill version